Two ALS programs, two modalities, one protein. AcuraStem's ASO and VectorY's vectorized antibody are starting to give the 97% of ALS patients without SOD1 mutations a real toolbox.
Tacalyx pulls €11M seed extension to push glycan-targeted ADC TCX-201 toward 2027 CTA filing.
Hypervision Surgical pulls £17M Series A for an FDA-cleared hyperspectral imaging platform that uses AI to differentiate tumor, nerves, and blood vessels in real-time during surgery.
Theolytics doses first patient in OCTOPOD-IP for THEO-260, an oncolytic virus targeting both ovarian tumors and CAFs.
Coultreon raises $125M Series A on 15 years of Galapagos SIK biology, advancing oral SIK3 inhibitor in immunology.
A roundup of the early-stage in vivo CAR-T signals we've covered this month, from preclinical to first-in-human.
TRex Bio doses first AD patient with TRB-061, a TNFR2 agonist that expands tissue-resident Tregs instead of suppressing inflammation.
EvolveImmune triggers $18M milestone from AbbVie partnership advancing trispecific T cell engagers with CD2 costimulation.
Kestrel doses first patient in pan-KRAS Phase 1 with AbbVie holding a warrant to acquire the company.
Scancell's iSCIB1+ DNA vaccine hits 77% PFS at 20 months in melanoma SCOPE trial, lands FDA Fast Track.
